MarketCap
Facebook
X
TelegramQuartalsbericht 2024-Q3
hinzugefügt 05.11.2024
Catalent Betriebsaufwand 2011-2025 | CTLT
Betriebsaufwand Jährlich Catalent
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 512 M | 463 M | 403 M | 358 M | 337 M | 335 M | 341 M | 339 M | 300 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 512 M | 300 M | 376 M |
Betriebsaufwand anderer Aktien in der Arzneimittelhersteller
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
133 M | $ 0.74 | -3.16 % | $ 52.6 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
197 M | $ 1.68 | -3.51 % | $ 181 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
154 M | $ 3.09 | -5.45 % | $ 1.63 B | Canada |
 |
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
183 M | $ 5.22 | -3.43 % | $ 86.3 M | Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
213 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
558 M | $ 11.73 | 2.71 % | $ 601 M | USA |
 |
Evoke Pharma
EVOK
|
12.6 M | $ 10.97 | 0.18 % | $ 36.7 M | USA |
 |
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
196 M | $ 21.42 | 0.28 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
107 M | $ 7.13 | 1.21 % | $ 442 M | USA |
 |
Harrow Health
HROW
|
90.1 M | $ 46.05 | -2.15 % | $ 1.5 B | USA |
 |
China Pharma Holdings
CPHI
|
2.6 M | $ 1.53 | -1.92 % | $ 26.7 M |  China |
 |
Bausch Health Companies
BHC
|
4.96 B | $ 6.8 | -1.81 % | $ 2.48 B | Canada |
 |
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
368 M | $ 4.89 | 1.45 % | $ 644 M | USA |
 |
OrganiGram Holdings
OGI
|
41.4 M | $ 1.84 | -4.43 % | $ 402 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 2.95 | 16.6 % | $ 41.5 M | USA |
 |
Pacira BioSciences
PCRX
|
279 M | $ 26.59 | 1.12 % | $ 1.23 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
55.6 M | - | - | $ 193 M | Canada |
 |
Rockwell Medical
RMTI
|
31.1 M | $ 0.9 | -2.76 % | $ 21 M | USA |
 |
Solid Biosciences
SLDB
|
130 M | $ 5.81 | -1.11 % | $ 237 M | USA |
 |
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 3.44 | -4.18 % | $ 4.27 M | USA |
 |
Relmada Therapeutics
RLMD
|
104 M | $ 4.07 | 0.25 % | $ 123 M | USA |
 |
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
1.43 B | $ 13.0 | -1.03 % | $ 1.79 B | USA |
 |
ProPhase Labs
PRPH
|
47.1 M | $ 0.11 | -4.97 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
102 K | $ 2.08 | -5.96 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | USA |
 |
Veru
VERU
|
44 M | $ 2.46 | 1.6 % | $ 332 M | USA |
 |
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
67.5 M | $ 0.64 | -1.5 % | $ 30.6 M | USA |
 |
cbdMD
YCBD
|
28.9 M | $ 1.55 | 28.75 % | $ 6.68 M | USA |
 |
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
1.52 B | $ 11.11 | -8.58 % | $ 6.87 B | Canada |
 |
TherapeuticsMD
TXMD
|
9.82 M | $ 1.74 | -0.86 % | $ 18.2 M | USA |
 |
Zomedica Corp.
ZOM
|
14.1 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
4.88 B | $ 11.68 | 0.26 % | $ 14.2 B | USA |